Ctrl Worx Watch List › Company

Regenerative Medical Technology Group Inc. (RMTG): material weakness open at least 2,403 days

By , Ctrl Worx™. Built from its own SEC filings. How the Clock works.

Regenerative Medical Technology Group Inc. reported ineffective internal control over financial reporting because of a material weakness in 1 filing since Apr 13, 2021. It stated one or more material weaknesses in 25 more SEC filings that gave no conclusion on whether that control is effective. The latest was its 10-Q for the period ended Jun 30, 2026.

Ctrl Worx Watch List™ status

On the Clock
6.6 yearsopen since at least Mar 31, 2020
10-Q, Aug 19, 2026latest filing that reports the weakness. Read it on SEC EDGAR
#17 of 1,250on the Clock by time open, tied with 3 other companies that share its start date. See the Clock

Still filing, and no annual report of its own says the weakness is fixed.

Checked against SEC EDGAR: Oct 29, 2026 · Entry #11450

Filings with a weakness26
First in our dataJan 7, 2021
AuditorVictor Mokuolu CPA PLLC

Causes the company named

Entity-level and governance · 26Financial close and reporting · 19Complex or non-routine accounting · 17Segregation of duties · 13Accounting expertise and resources · 7Other · 1

What the latest filing says

Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses described below. 1. We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act which is applicable to us for the year ended December 31, 2025. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness. 2. We have inadequate controls to ensure that information necessary to properly record transactions is adequately communicated on a timely basis from non-financial personnel to those responsible for financial reporting. Management evaluated the impact of the lack of timely communication between non–f [...]

From the controls section of the 10-Q filed Aug 19, 2026. Read the full filing on SEC EDGAR.

Company response: Regenerative Medical Technology Group Inc. can send a statement or a link to its remediation update to russell@ctrlworx.com. We post it here, unedited and dated.

Filings

FiledFormPeriodControlsCausesFiling
Aug 19, 202610-QJun 30, 2026Material weakness stated, no ICFR conclusionEntity-level and governanceEDGAR
Jun 9, 202610-QMar 31, 2026Material weakness stated, no ICFR conclusionFinancial close and reporting; Entity-level and governanceEDGAR
May 14, 202610-KDec 31, 2025Material weakness stated, no ICFR conclusionFinancial close and reporting; Entity-level and governanceEDGAR
Nov 19, 202510-QSep 30, 2025Material weakness stated, no ICFR conclusionFinancial close and reporting; Complex or non-routine accounting; Entity-level and governanceEDGAR
Aug 19, 202510-QJun 30, 2025Material weakness stated, no ICFR conclusionFinancial close and reporting; Complex or non-routine accounting; Entity-level and governanceEDGAR
May 20, 202510-QMar 31, 2025Material weakness stated, no ICFR conclusionFinancial close and reporting; Complex or non-routine accounting; Entity-level and governanceEDGAR
Apr 15, 202510-KDec 31, 2024Material weakness stated, no ICFR conclusionFinancial close and reporting; Complex or non-routine accounting; Entity-level and governanceEDGAR
Nov 19, 202410-QSep 30, 2024Material weakness stated, no ICFR conclusionFinancial close and reporting; Complex or non-routine accounting; Entity-level and governanceEDGAR
Aug 14, 202410-QJun 30, 2024Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; Entity-level and governanceEDGAR
May 20, 202410-QMar 31, 2024Material weakness stated, no ICFR conclusionFinancial close and reporting; Complex or non-routine accounting; Entity-level and governanceEDGAR
Apr 15, 202410-KDec 31, 2023Material weakness stated, no ICFR conclusionFinancial close and reporting; Complex or non-routine accounting; Entity-level and governanceEDGAR
Nov 20, 202310-QSep 30, 2023Material weakness stated, no ICFR conclusionFinancial close and reporting; Complex or non-routine accounting; Entity-level and governanceEDGAR
Aug 9, 202310-QJun 30, 2023Material weakness stated, no ICFR conclusionFinancial close and reporting; Complex or non-routine accounting; Entity-level and governanceEDGAR
May 22, 202310-QMar 31, 2023Material weakness stated, no ICFR conclusionFinancial close and reporting; Complex or non-routine accounting; Entity-level and governanceEDGAR
Apr 14, 202310-KDec 31, 2022Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; Entity-level and governanceEDGAR
Nov 9, 202210-QSep 30, 2022Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; Entity-level and governanceEDGAR
Aug 15, 202210-QJun 30, 2022Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; Entity-level and governanceEDGAR
May 19, 202210-QMar 31, 2022Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; Entity-level and governanceEDGAR
May 5, 202210-KDec 31, 2021Material weakness stated, no ICFR conclusionSegregation of duties; Complex or non-routine accounting; Entity-level and governanceEDGAR
Dec 22, 202110-QSep 30, 2021Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Complex or non-routine accounting; Entity-level and governanceEDGAR
Aug 13, 202110-QJun 30, 2021Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
May 17, 202110-QMar 31, 2021Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Apr 13, 202110-KDec 31, 2020Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Feb 24, 202110-QSep 30, 2020Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Feb 8, 202110-QJun 30, 2020Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Jan 7, 202110-QMar 31, 2020Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governance; OtherEDGAR

Others on the Clock in the same industry

By SEC industry code: 5990, Retail-Retail Stores, NEC, then related codes.

Follow RMTG for free

Get an email when Regenerative Medical Technology Group Inc files a 10-K or 10-Q that reports a material weakness, or says its controls are effective again.

Want the next one the day it's filed?

MW Pro sends an alert the day a company you follow reports a material weakness or says it fixed one. Founding price $990 a year.

Join the MW Pro waitlistLook up any company in Controls Radar™

Watch List Weekly: new material weaknesses, fixes and the longest-running cases, every Monday.

One email to confirm, then one email each Monday. Every email has a one-click unsubscribe. Privacy policy

Based on public SEC filings. Causes are grouped into standard categories by Ctrl Worx. The filings are the authority. Ctrl Worx is not affiliated with Regenerative Medical Technology Group Inc. or the SEC. Not investment advice. Why you can rely on the Watch List.